When to recommend allogeneic transplant in multiple myeloma

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

Original languageEnglish (US)
Pages (from-to)2512-2517
Number of pages6
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2 2015


  • Allogeneic transplant
  • matched donors
  • matched-unrelated donors
  • multiple myeloma
  • reduced-intensity conditioning
  • transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'When to recommend allogeneic transplant in multiple myeloma'. Together they form a unique fingerprint.

Cite this